Sign in
Enrolling by invitationNo phase

Long-term follow-up of people who received EDIT-301 for sickle cell or thalassemia

Follows people with sickle cell disease or beta-thalassemia who received EDIT-301 over time.

Key facts

Who runs it
Editas Medicine, Inc.
Where
Atlanta, Aurora, Charleston, Charlotte, Cleveland, Columbus, Dallas, Fort Worth, Minneapolis, Nashville, New Haven, New York, Oakland, Philadelphia, and St. Petersburg, United StatesSee the 16 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Status
Enrolling by invitation
People taking part
54 people, planned
Started
17 Jun 2024
Expected to end
Aug 2040
Type of study
Observational
Treatments tested
  • Safety and efficacy assessments
Record updated
2 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with severe sickle cell disease or transfusion-dependent β-thalassemia who already received an EDIT-301 infusion in another study. It follows their safety and results over the long term.

Age
12 to 50 years
Sex
All sexes can join.
Disease stage
Severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT).
Earlier treatment
Must have received an EDIT-301 infusion as part of a clinical study.

Main reasons for not taking part

  • Still actively taking part in an EDIT-301 treatment study and not yet ready for long-term follow-up in this study

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participant must have received an EDIT-301 infusion as part of a clinical study
  • Participant or legal representative/guardian (if applicable) must sign and date the informed consent form (ICF) or assent, if applicable for this long-term follow-up study

Who cannot take part

  • Participant is still actively enrolled in an EDIT-301 treatment study and has not yet met eligibility for long term follow-up in this study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 50 years old?

Where in United States

Also in 1 other country, 2 sites

  • Children's Healthcare of AtlantaAtlanta, United StatesEnrolling by invitation
  • Children's Hospital ColoradoAurora, United StatesEnrolling by invitation
  • Medical University of South CarolinaCharleston, United StatesEnrolling by invitation
  • Atrium HealthCharlotte, United StatesEnrolling by invitation
  • Cleveland ClinicCleveland, United StatesEnrolling by invitation
  • Nationwide Children's HospitalColumbus, United StatesEnrolling by invitation
  • Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, United StatesEnrolling by invitation
  • Cook Children'sFort Worth, United StatesEnrolling by invitation
  • University of MinnesotaMinneapolis, United StatesEnrolling by invitation
  • Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood CancersNashville, United StatesEnrolling by invitation
  • Smilow Cancer HospitalNew Haven, United StatesEnrolling by invitation
  • Columbia University Medical CenterNew York, United StatesEnrolling by invitation
  • Columbia University Medical Center - Department of PediatricsNew York, United StatesEnrolling by invitation
  • UCSF Benioff Children s HospitalOakland, United StatesEnrolling by invitation
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
  • Johns Hopkins All Children's HospitalSt. Petersburg, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

The group in the trial

  • All participants

    All participants who complete or discontinue one of the parent studies (EM-SCD-301-001 or EDIT-301-BThal-001)

    Treatment: Safety and efficacy assessments

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Plain-language title
Long-term follow-up of people who received EDIT-301 for sickle cell or thalassemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06363760, who can take part
Record updated
2 April 2025